Skip Navigation

watchlive

Pre-Markets
U.S. Markets
Currencies
Cryptocurrency
Futures & Commodities
Bonds
Funds & ETFs

Economy
Finance
Health & Science
Media
Real Estate
Energy
Climate
Transportation
Industrials
Retail
Wealth
Sports
Life
Small Business

Personal Finance
Fintech
Financial Advisors
Options Action
ETF Street
Buffett Archive
Earnings
Trader Talk

Cybersecurity
Enterprise
Internet
Media
Mobile
Social Media
CNBC Disruptor 50
Tech Guide

White House
Policy
Defense
Congress
Equity and Opportunity

Live TV
Live Audio
Business Day Shows
Entertainment Shows
Full Episodes
Latest Video
Top Video
CEO Interviews
CNBC Documentaries
CNBC Podcasts
CNBC World
Digital Originals
Live TV Schedule

Trust Portfolio
Analysis
Trade Alerts
Meeting Videos
Homestretch
Jim's Columns
Education
Subscribe
Sign In

Pro News
Pro Live
Stock Screener
Market Forecast
Options Investing
Subscribe
Sign In

Make It

USA
INTL

watchlive

Goldman Sachs has a bunch of new buy-rated stocks — and says 5 have upside of more than 90%

Published Sun, Jan 16 20226:40 PM EST

Goldman Sachs has given 49 stocks a "buy" rating since Jan. 1 — and a look at the list reveals five that the bank says could rally more than 90% over the next 12 months. Dynavax Technologies California-based biotechnology firm Dynavax Technologies is one such stock. Goldman's analyst Madhu Kumar reinstated the stock to "buy" in a research note on Jan. 5, as he noted the "considerable" potential revenue stream from the company's Covid-19 vaccine adjuvant — an ingredient used in vaccines to create a stronger immune response. Over the longer term, the bank is "bullish" on the company's hepatitis B virus (HBV) vaccine Heplisav-B, which it believes has a potential to be "best-in-class." A recent recommendation by the U.S. Centre for Disease Control and Prevention for universal HBV vaccination in the U.S. could lead to a a 50% expansion of the virus vaccine market, Kumar said. The bank forecasts sales of the company's Covid-19 adjuvant t o hit $517.5 million this year, while Heplisav-B is expected to generate revenues of $536.1 million by 2030, Kumar said in the company's initiation note on Aug. 5. Goldman has a price target of $38 on the stock, which closed at around $13 on Jan. 13 — an implied potential upside of 191%. Nerdy The bank also likes live online learning platform Nerdy . The company provides both paid and free classes in the U.S via its online platform — a market which Goldman expects to be valued at $69 billon by 2026. Analyst Eric Sheridan said in his initiation note on Jan. 6 that Covid-19 had accelerated the shift from offline to online learning, which he expects will benefit Nerdy in the longer-term. Goldman has forecast revenue growth of 30% for the company into 2026, when it is expected to hit $519 million. The bank's price target of $8 on the stock implies a potential upside of 91% to its closing price of $4.20 on Jan. 13. Planet Labs Goldman initiated coverage on U.S. satellite imaging company Planet Labs i n January, describing the compa